MBRX
ACHAT TOTAL: 533 333 titres (~399 999,75 $ US)
- Insiders
- KLEMP WALTER V
- Total bought
- $400,000
- Total sold
- —
- Last activity
- 2026-08-03
- Last synced
-
2026-08-09 12:58:10
Insider holdings as a share of total assets aren't available for this company.
Price (1 year)
Live chart from TradingView - pulls its own market data, independent of this site's database. Symbol resolution is best-effort (defaults to NASDAQ) since we don't store the exchange prefix.
Market snapshot
Signal
Bearish signal Scored 2026-08-26
MBRX presents a critically weak financial foundation with near-zero liquidity (25) and deteriorating fundamentals (15), characteristic of a pre-revenue shell with acute insolvency risk.
The first sentence of the analysis written for MBRX on 2026-08-26 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Ebit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Ebitda Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Operating Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Pretax Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Continuous Operations Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Net Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Bottom Line Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Current Ratio | 1.413 | 0.969 | 3.855 | 9.462 | 20.016 | |
| Quick Ratio | 1.413 | 0.969 | 3.855 | 9.462 | 20.016 | |
| Solvency Ratio | -4.701 | -1.977 | -2.441 | -5.524 | -3.086 | |
| Cash Ratio | 1.295 | 0.798 | 3.456 | 8.953 | 19.576 | |
| Price To Earnings Ratio | -0.116 | -0.225 | -0.855 | -1.045 | -3.145 | |
| Price To Earnings Growth Ratio | 0.001 | 0.005 | 0.856 | -0.015 | 0.047 | |
| Forward Price To Earnings Growth Ratio | 0.001 | 0.005 | 0.856 | -0.015 | 0.047 | |
| Price To Earnings Diluted Ratio | -0.116 | -0.225 | -0.855 | -1.045 | -3.145 | |
| Price To Earnings Diluted Growth Ratio | 0.001 | 0.005 | 0.856 | -0.015 | 0.047 | |
| Price To Book Ratio | 0.261 | 0.979 | 0.976 | 0.581 | 0.633 | |
| Price To Sales Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Price To Free Cash Flow Ratio | -0.172 | -0.245 | -1.050 | -1.094 | -2.635 | |
| Price To Operating Cash Flow Ratio | -0.172 | -0.245 | -1.056 | -1.097 | -2.638 | |
| Debt To Assets Ratio | 0.016 | 0.028 | 0.015 | 0.008 | 0.002 | |
| Debt To Equity Ratio | 0.024 | 0.080 | 0.022 | 0.009 | 0.002 | |
| Debt To Capital Ratio | 0.023 | 0.074 | 0.022 | 0.009 | 0.002 | |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Financial Leverage Ratio | 1.474 | 2.831 | 1.466 | 1.100 | 1.065 | |
| Working Capital Turnover Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Ratio | -3.317 | -4.453 | -3.536 | -5.735 | -5.232 | |
| Operating Cash Flow Sales Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Free Cash Flow Operating Cash Flow Ratio | 1.000 | 1.001 | 1.005 | 1.002 | 1.001 | |
| Debt Service Coverage Ratio | -244.307 | 0.000 | 0.000 | 0.000 | -163.854 | |
| Interest Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Short Term Operating Cash Flow Coverage Ratio | -165.949 | 0.000 | 0.000 | 0.000 | -197.406 | |
| Operating Cash Flow Coverage Ratio | -63.329 | -49.921 | -41.988 | -61.284 | -119.189 | |
| Capital Expenditure Coverage Ratio | 0.000 | -1,835.538 | -194.363 | -412.522 | -997.421 | |
| Dividend Paid And Capex Coverage Ratio | 0.000 | -1,835.538 | -194.363 | -412.522 | -997.421 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | 0.137 | -0.095 | -0.083 | 0.428 | 1.319 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 0.0% | 0.0% | 0.0% |
| Ebit Margin | 0.0% | 0.0% | 0.0% |
| Ebitda Margin | 0.0% | 0.0% | 0.0% |
| Operating Profit Margin | 0.0% | 0.0% | 0.0% |
| Pretax Profit Margin | 0.0% | 0.0% | 0.0% |
| Continuous Operations Profit Margin | 0.0% | 0.0% | 0.0% |
| Net Profit Margin | 0.0% | 0.0% | 0.0% |
| Bottom Line Profit Margin | 0.0% | 0.0% | 0.0% |
| Current Ratio | 1.413 | ▲0.444 | ▼-5.730 |
| Quick Ratio | 1.413 | ▲0.444 | ▼-5.730 |
| Solvency Ratio | -4.701 | ▼-2.724 | ▼-1.155 |
| Cash Ratio | 1.295 | ▲0.497 | ▼-5.520 |
| Price To Earnings Ratio | -0.117 | ▲0.108 | ▲0.961 |
| Price To Earnings Growth Ratio | 0.001 | ▼-0.003 | ▼-0.177 |
| Forward Price To Earnings Growth Ratio | 0.001 | ▼-0.003 | ▼-0.177 |
| Price To Earnings Diluted Ratio | -0.117 | ▲0.108 | ▲0.961 |
| Price To Earnings Diluted Growth Ratio | 0.001 | ▼-0.003 | ▼-0.177 |
| Price To Book Ratio | 0.261 | ▼-0.718 | ▼-0.425 |
| Price To Sales Ratio | 0.000 | 0.000 | 0.000 |
| Price To Free Cash Flow Ratio | -0.172 | ▲0.073 | ▲0.867 |
| Price To Operating Cash Flow Ratio | -0.172 | ▲0.073 | ▲0.869 |
| Debt To Assets Ratio | 0.016 | ▼-0.012 | ▲0.002 |
| Debt To Equity Ratio | 0.024 | ▼-0.056 | ▼-0.003 |
| Debt To Capital Ratio | 0.023 | ▼-0.051 | ▼-0.003 |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | 0.000 |
| Financial Leverage Ratio | 1.474 | ▼-1.356 | ▼-0.113 |
| Working Capital Turnover Ratio | 0.000 | 0.000 | 0.000 |
| Operating Cash Flow Ratio | -3.317 | ▲1.136 | ▲1.138 |
| Operating Cash Flow Sales Ratio | 0.000 | 0.000 | 0.000 |
| Free Cash Flow Operating Cash Flow Ratio | 1.000 | ▼-0.001 | ▼-0.002 |
| Debt Service Coverage Ratio | -244.307 | ▼-244.307 | ▼-162.674 |
| Interest Coverage Ratio | 0.000 | 0.000 | 0.000 |
| Short Term Operating Cash Flow Coverage Ratio | -165.949 | ▼-165.949 | ▼-93.278 |
| Operating Cash Flow Coverage Ratio | -63.329 | ▼-13.408 | ▲3.813 |
| Capital Expenditure Coverage Ratio | 0.000 | ▲1835.539 | ▲687.969 |
| Dividend Paid And Capex Coverage Ratio | 0.000 | ▲1835.539 | ▲687.969 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | 0.137 | ▲0.232 | ▼-0.204 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $3.9M | $5.9M | $25.4M | $30.3M | $50.0M | |
| Enterprise value | -$4.6M | $2.1M | $2.5M | -$12.4M | -$20.8M | |
| EV / Sales | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | |
| EV / Op. cash flow | 0.20x | -0.09x | -0.10x | 0.45x | 1.09x | |
| EV / Free cash flow | 0.20x | -0.09x | -0.10x | 0.45x | 1.09x | |
| EV / EBITDA | 0.14x | -0.10x | -0.08x | 0.43x | 1.32x | |
| Net debt / EBITDA | 0.26x | 0.18x | 0.78x | 1.48x | 4.50x | |
| Current ratio | 1.41x | 0.97x | 3.85x | 9.46x | 20.02x | |
| Income quality | 0.68x | 1.10x | 0.81x | 0.95x | 1.19x | |
| Graham net-net | $1 | -$48 | $144 | $497 | $919 | |
| Tax burden | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| Interest burden | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| Working capital | $2.8M | -$165K | $19.5M | $40.8M | $68.9M | |
| Invested capital | $14.3M | $11.6M | $31.4M | $52.6M | $80.5M | |
| Return on assets | -151.7% | -128.6% | -77.9% | -50.5% | -18.9% | |
| Operating ROA | -128.6% | -96.6% | -62.0% | -43.3% | -40.6% | |
| Return on tangible assets | -305.7% | -376.7% | -110.0% | -62.7% | -21.8% | |
| Return on equity | -223.6% | -364.0% | -114.2% | -55.6% | -20.1% | |
| Return on invested capital | -162.9% | -228.0% | -94.1% | -58.1% | -28.5% | |
| Return on capital employed | -164.4% | -230.3% | -94.4% | -58.2% | -28.5% | |
| Earnings yield | -855.9% | -371.8% | -117.0% | -95.7% | -31.8% | |
| Free cash flow yield | -579.8% | -407.9% | -95.2% | -91.4% | -37.9% | |
| Capex / Op. cash flow | 0.0% | -0.1% | -0.5% | -0.2% | -0.1% | |
| Capex / Depreciation | 0.0% | 10.3% | 97.6% | 51.5% | 11.6% | |
| Capex / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| SG&A / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| R&D / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Stock comp / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Intangibles / Total assets | 50.4% | 65.9% | 29.2% | 19.4% | 13.3% | |
| Days sales outstanding | 0d | 0d | 0d | 0d | 0d | |
| Days payables outstanding | 14227d | 0d | 0d | 0d | 0d | |
| Operating cycle | 0d | 0d | 0d | 0d | 0d | |
| Cash conversion cycle | -14227d | 0d | 0d | 0d | 0d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Valuation
Market cap ▼-33.0%EV / Sales n/aEV / EBITDA ▲+244.8%EV / Op. cash flow ▲+0.288Earnings yield ▼-4.841
Profitability
Return on equity ▲+1.403Return on assets ▼-0.231Return on invested capital ▲+0.651Return on capital employed ▲+0.660Operating ROA ▼-0.319Income quality ▼-0.419Tax burden 0.000
Efficiency
Days sales outstanding n/aDays payables outstanding n/aOperating cycle n/aCash conversion cycle n/aCapex / Sales n/aR&D / Sales n/a
Balance-sheet strength
Current ratio ▲+0.444Net debt / EBITDA ▲+0.079Working capital ▲+2997000.000Invested capital ▲+2728000.000Intangibles / Total assets ▼-0.155
Change over 5 years
Valuation
Market cap ▼-92.2%EV / Sales n/aEV / EBITDA ▼-89.6%EV / Op. cash flow ▼-0.893Earnings yield ▼-8.241
Profitability
Return on equity ▼-2.035Return on assets ▼-1.328Return on invested capital ▼-1.344Return on capital employed ▼-1.358Operating ROA ▼-0.880Income quality ▼-0.515Tax burden 0.000
Efficiency
Days sales outstanding n/aDays payables outstanding n/aOperating cycle n/aCash conversion cycle n/aCapex / Sales n/aR&D / Sales n/a
Balance-sheet strength
Current ratio ▼-18.603Net debt / EBITDA ▼-4.243Working capital ▼-66043000.000Invested capital ▼-66174000.000Intangibles / Total assets ▲+0.371
Employee count
Peer market caps
Congressional trades
No congressional trade data synced.
Recent news
- 2026-07-31 Moleculin Announces Pricing of $9.3 Million Public Offering HOUSTON, July 31, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), today announced the pricing of a best-efforts public offering of an aggregate of 12,376,667 shares of common stock (or pre-funded warrants in lieu thereof), and warrants (the “Common Warrants”) to purchase up to 37,130,001 shares of common stock at a combined public offering price of $0.75 per share of common stock (or pre-funded warrant in lieu thereof) and associated warrants. The Common Warrants will be immediately exercisable at an exercise price of $0.75 per share and will expire five years following the initial exercise date. The offering is expected to close on or about August 3, 2026, subject to satisfaction of customary closing conditions.
- 2026-07-31 Moleculin Announces Pricing of $9.3 Million Public Offering HOUSTON, July 31, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc. , (Nasdaq: MBRX) ("Moleculin" or the "Company"), today announced the pricing of a best-efforts public offering of an aggregate of 12,376,667 shares of common stock (or pre-funded warrants in lieu thereof), and warrants (the "Common Warrants") to purchase up to 37,130,001 shares of common stock at a combined public offering price of $0.
- 2026-07-31 Moleculin’s MIRACLE R/R AML Trial Reports Positive Interim Data with 37% Blinded CRc in Venetoclax-Failed Patients Prior venetoclax failure - a setting in which published salvage remission rates are approximately 13% and median survival approximately 2. 4 months - shows no adverse impact on blinded composite remission rates as MIRACLE approaches the end of Part A Preliminary blinded CR of 24% and CRc of 37% (n=62), with essentially identical rates among the 30 patients who had failed first-line venetoclax: CR of 23% and CRc of 37% (3X the published salvage remission rates following first-line venetoclax failure of approximately 13%) Enrollment reaches 74 of 90 patients, with final Part A treatment expected in September 2026 and comprehensive unblinded Part A results on track for the planned December 2026-February 2027 timeframe No evidence of cardiotoxicity continues to differentiate Annamycin from conventional anthracyclines HOUSTON, July 31, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc.
- 2026-07-31 Moleculin''s MIRACLE R/R AML Trial Reports Positive Interim Data with 37% Blinded CRc in Venetoclax-Failed Patients Prior venetoclax failure — a setting in which published salvage remission rates are approximately 13% and median survival approximately 2.4 months — shows no adverse impact on blinded composite remission rates as MIRACLE approaches the end of Part A
- 2026-07-06 Moleculin CEO, Walter Klemp, Highlights Positive Preliminary MIRACLE Trial Results in Virtual Investor "What This Means" Segment Access the segment here HOUSTON, July 06, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc. , (Nasdaq: MBRX) ("Moleculin" or the "Company"), today announced that Walter Klemp, Chairman and Chief Executive Officer of Moleculin, participated in a Virtual Investor "What This Means" segment.
- 2026-07-06 Moleculin CEO, Walter Klemp, Highlights Positive Preliminary MIRACLE Trial Results in Virtual Investor "What This Means" Segment HOUSTON, July 06, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), today announced that Walter Klemp, Chairman and Chief Executive Officer of Moleculin, participated in a Virtual Investor “What This Means” segment.
- 2026-06-30 Why is Moleculin Stock Falling Today? Moleculin Biotech Inc. (NASDAQ:MBRX) stock is trading lower on Tuesday after the company shared preliminary efficacy data from the first 45 patients enrolled in Part A of its pivotal Phase 2/3 MIRACLE trial that did not reach statistical significance.
- 2026-06-30 Moleculin Reports Positive Phase 2/3 MIRACLE Interim Results, With Annamycin Complete Remission Rates 3-fold Greater than Control Both Annamycin dose arms outperformed control on the primary endpoint of complete remission (CR): 43% and 36% versus 12% — reported on a full intent-to-treat (ITT) basis with no patient exclusions Composite complete remission (CRc) reached 50% and 57% in the respective Annamycin arms versus 29% for control Enrollment in the MIRACLE trial continues with more than two-thirds (67 of 90 subjects) of Part A target as Company advances toward optimal dose selection HOUSTON, June 30, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), today announced positive preliminary unblinded efficacy results from the first 45 patients enrolled in Part A of the Company''s pivotal Phase 2/3 MIRACLE trial, analyzed on a full intent-to-treat basis with no patient exclusions. Both Annamycin treatment arms demonstrated favorable efficacy trends compared with the control arm in patients with relapsed or refractory acute myeloid leukemia (R/R AML).
- 2026-06-05 Independent Market Research Finds Strong Physician Intent to Prescribe Moleculin''s Annamycin in Relapsed/Refractory AML Surveyed oncologists reported high likelihood to prescribe (6 of 7), citing deep remissions, transplant-bridging potential, biomarker-agnostic use and reduced cardiotoxicity as key drivers
- 2026-06-04 Moleculin CEO, Walter Klemp, Highlights 45 Subject Enrollment Milestone in Recent Virtual Investor “What This Means” Segment - Access the segment here HOUSTON, June 04, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc. , (Nasdaq: MBRX) ("Moleculin" or the "Company"), today announced that Walter Klemp, Chairman and Chief Executive Officer of Moleculin, participated in a Virtual Investor "What This Means" segment.